Skip to main content

Table 4 Sustained Virologic Response Rates (95% Confidence Intervals) in Patients infected with HCV Genotype 2, 4, and 6

From: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

 Genotype 2 SVR, % (95% CI)Genotype 4 SVR, % (95% CI)Genotype 6 SVR, % (95% CI)
All patientsDAC + SOFSOF/VELAll patientsLDV/SOFDAC + SOFAll patientsLDV/SOFDAC + SOFSOF/VEL
Patients who complete, N1410411110152361097
 All durations100 (78.5–100)100 (72.2–100)100 (51.0–100)90.9 (62.3–98.4)100 (20.7–100)90.0 (59.6–98.2)96.7 (92.5–98.6)97.2 (85.8–99.5)96.3 (90.9–98.6)100 (64.6–100)
 12-wk treatment100 (77.2–100)100 (70.1–100)100 (51.0–100)87.5 (52.9–97.8)100 (20.7–100)85.7 (48.7–97.4)97.1 (92.9–98.9)97.0 (84.7–99.5)97.0 (91.5–99.0)100 (64.6–100)
 16-wk treatmentNANANANANANA100 (34.2–100)NA100 (34.2–100)NA
 24-wk treatment100 (20.7–100)100 (20.7–100)NA100 (43.9–100)NA100 (43.9–100)90.0 (59.6–98.2)100 (43.9–100)85.7 (48.7–97.4)NA
SVR in the following subgroups
 No cirrhosis100 (74.1–100)100 (64.6–100)100 (51.0–100)100 (61.0–100)100 (20.7–100)100 (56.6–100)96.8 (90.9–98.9)100 (82.4–100)95.8 (88.5–98.6)100 (43.9–100)
 Cirrhosis100 (43.9–100)100 (43.9–100)NA80.0 (37.6–96.4)NA80.0 (37.6–96.4)96.6 (88.5–99.1)94.4 (74.2–99.0)97.3 (86.2–99.5)100 (51.0–100)
 Decompensated cirrhosis100 (20.7–100)100 (20.7–100)NA100 (20.7–100)NA100 (20.7–100)100 (67.6–100)100 (34.2–100)100 (56.6–100)100 (20.7–100)
 Treatment-naive100 (75.8–100)100 (67.6–100)100 (51.0–100)83.3 (43.6–97.0)NA83.3 (43.6–97.0)99.1 (94.8–99.8)100 (88.6–100)98.6 (92.3–99.7)100 (61.0–100)
 Treatment-experienced100 (34.2–100)100 (34.2–100)NA100 (56.6–100)100 (20.7–100)100 (51.0–100)91.3 (79.7–96.6)83.3 (43.6–97.0)92.3 (79.7–97.3)100 (20.7–100)